With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23462-75-1,Dihydro-2H-pyran-3(4H)-one,as a common compound, the synthetic route is as follows.
POC13 (3.1 g, 20.0 mmol, 1 eq) was added dropwise to DMF (1.46 g, 20.0 mmol, 1 eq) over 5 minutes at 0C. Dichloromethane (10mL) was added and then the ice-bath was removed. The reaction was kept at 25C for 1 hour, then it was cooled to 0C again. Dihydro-2H-pyran-3(4H)-one 1-4 (2 g, 20.0 mmol, 1 eq) in 5 mL of dichloromethane was added dropwise within 5 minutes. The reaction was kept at 0C for 1 hour. The reaction mixture was quenched by adding 20 mL of sat. NH4C1, and extracted three times with 30 mL of DCM. The combined organic phases were washed with 20 mL of brine,dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (Si02 eluting with a gradient of petroleum ether: ethyl acetate = 50:1 to 20:1) to give 470 mg of compound 1-5 as a yellow oil.
23462-75-1, As the paragraph descriping shows that 23462-75-1 is playing an increasingly important role.
Reference£º
Patent; AQUINNAH PHARMACEUTICALS, INC.; BURNETT, Duane, A.; VACCA, Joseph, P.; (310 pag.)WO2018/119395; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics